These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36708129)

  • 81. Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females.
    Sogabe M; Okahisa T; Kurihara T; Kagawa M; Ueda H; Kawaguchi T; Fukuya A; Kagemoto K; Tanaka H; Kida Y; Tomonari T; Taniguchi T; Okamoto K; Miyamoto H; Sato Y; Nakasono M; Takayama T
    Sci Rep; 2022 Sep; 12(1):16048. PubMed ID: 36163355
    [TBL] [Abstract][Full Text] [Related]  

  • 82. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
    Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
    Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes.
    Yu C; Wang L; Xue H; Lin H; Li Y; Chan SO
    Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):58-66. PubMed ID: 30274911
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
    Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient Truths.
    Armstrong MJ; Mellinger JL; Trivedi PJ
    Am J Gastroenterol; 2018 Oct; 113(10):1437-1439. PubMed ID: 30166633
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
    Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different.
    Malnick SDH; Alin P; Somin M; Neuman MG
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555867
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD.
    Önnerhag K; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2014 Sep; 49(9):1111-8. PubMed ID: 24990583
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
    Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Epidemiology of Non-alcoholic Fatty Liver Disease in North America.
    Arshad T; Golabi P; Henry L; Younossi ZM
    Curr Pharm Des; 2020; 26(10):993-997. PubMed ID: 32124690
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Independent and joint effects of moderate alcohol consumption and smoking on the risks of non-alcoholic fatty liver disease in elderly Chinese men.
    Liu P; Xu Y; Tang Y; Du M; Yu X; Sun J; Xiao L; He M; Wei S; Yuan J; Wang Y; Liang Y; Wu T; Miao X; Yao P
    PLoS One; 2017; 12(7):e0181497. PubMed ID: 28727853
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Bidirectional association between non-alcoholic fatty liver disease and fatty pancreas: a systematic review and meta-analysis.
    Wongtrakul W; Untaaveesup S; Pausawadi N; Charatcharoenwitthaya P
    Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1107-1116. PubMed ID: 37665612
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Does Advice Based on Biomarkers of Liver Injury or Non-Invasive Tests of Liver Fibrosis Impact High-Risk Drinking Behaviour: A Systematic Review With Meta-analysis.
    Subhani M; Knight H; Ryder S; Morling JR
    Alcohol Alcohol; 2021 Feb; 56(2):185-200. PubMed ID: 33479737
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
    Ng CH; Lim WH; Hui Lim GE; Hao Tan DJ; Syn N; Muthiah MD; Huang DQ; Loomba R
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):931-939.e5. PubMed ID: 35513235
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Coffee Consumption and the Progression of NAFLD: A Systematic Review.
    Sewter R; Heaney S; Patterson A
    Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371891
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?
    Petroni ML; Brodosi L; Marchignoli F; Musio A; Marchesini G
    Nutrients; 2019 Dec; 11(12):. PubMed ID: 31847199
    [TBL] [Abstract][Full Text] [Related]  

  • 98. An exploratory analysis of the competing effects of alcohol use and advanced hepatic fibrosis on serum HDL.
    Vannier AGL; PeBenito A; Fomin V; Chung RT; Schaefer E; Goodman RP; Luther J
    Clin Exp Med; 2022 Feb; 22(1):103-110. PubMed ID: 34212294
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Alcohol consumption and risk of fatty liver disease: a meta-analysis.
    Cao G; Yi T; Liu Q; Wang M; Tang S
    PeerJ; 2016; 4():e2633. PubMed ID: 27812428
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of Low-Dose Alcohol Consumption on Chronic Liver Disease.
    Andaloro S; Mancuso F; Miele L; Addolorato G; Gasbarrini A; Ponziani FR
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.